China permits human testing for COVID vaccine by Chongqing Zhifei

▴ china-permits-human-testing-covid-vaccine-chongqing-zhifei
Developers obtained a certificate from the National Medical Products Administration to launch clinical trials

The origin-country of Coronavirus China is now ready to test its indigenous vaccine, developed by Chongqing Zhifei Biological Products’ unit, on human beings, the corporate said during a filing on Tuesday.
Anhui Zhifei Longcom Biopharmaceutical jointly developed the vaccine along with the Institute of Microbiology of the Chinese Academy of Sciences and has obtained a certificate from the National Medical Products Administration to launch clinical trials.
Chinese researchers and corporations are starting with six shots in humans, while over a dozen vaccines are in several stages of clinical trials across the globe against the virus that has claimed over 470,000 lives.
Meanwhile, US-based Moderna has finalized the Phase 3 study protocol, which includes approximately 30,000 participants enrolled within the US to check its COVID-19 vaccine's efficacy on a larger scale.
The randomized, placebo-controlled trial is predicted to start in July.


"The company remains on target to be ready to deliver approximately 500 million doses per annum, and possibly up to 1 billion doses per annum, beginning in 2021 from the company’s internal US manufacturing site and strategic collaboration with Lonza," the corporate is quoted from a handout it issued.
“We anticipate beginning our Phase 3 study of mRNA-1273," said Tal Zaks, MD, Ph.D., Chief medic at Moderna, pertaining to the COVID-19 vaccine's code name.
“Moderna is committed to advancing the clinical development of mRNA-1273 as safely and quickly as possible to demonstrate our vaccine’s ability to significantly reduce the danger of COVID-19 disease,” he added.


On May 11, the Food and Drug Administration (FDA) granted the new drug (IND) application for mRNA-1273.
The Phase 1 study is ongoing with the first cohorts in long-term follow-up and enrollment in 9 of 12 cohorts complete. The National Institutes of Health (NIH) are going to be submitting the Phase 1 data to a peer-reviewed clinical publication.
This Phase 2 study is evaluating the security, reactogenicity, and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart.
There are about 160 vaccines that are under development with an aim to beat the Sars-Cov-2 coronavirus, which causes the COVID-19 disease. the continued pandemic has seen about 7.6 million people infected and has caused over 400,000 deaths.

Tags : #China #Vaccine #Coronavirus #COVID19 #US #HumanTesting

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Surviving Against the Odds: Steven Spinale's Journey After an Ingrown Hair Turns DeadlyMarch 29, 2024
10 reasons why media research and Planning are essential in Healthcare marketingMarch 29, 2024
The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024